Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells
© 2024. The Author(s), under exclusive licence to Springer Nature Limited..
Tiragolumab, an anti-TIGIT antibody with an active IgG1κ Fc, demonstrated improved outcomes in the phase 2 CITYSCAPE trial (ClinicalTrials.gov: NCT03563716 ) when combined with atezolizumab (anti-PD-L1) versus atezolizumab alone1. However, there remains little consensus on the mechanism(s) of response with this combination2. Here we find that a high baseline of intratumoural macrophages and regulatory T cells is associated with better outcomes in patients treated with atezolizumab plus tiragolumab but not with atezolizumab alone. Serum sample analysis revealed that macrophage activation is associated with a clinical benefit in patients who received the combination treatment. In mouse tumour models, tiragolumab surrogate antibodies inflamed tumour-associated macrophages, monocytes and dendritic cells through Fcγ receptors (FcγR), in turn driving anti-tumour CD8+ T cells from an exhausted effector-like state to a more memory-like state. These results reveal a mechanism of action through which TIGIT checkpoint inhibitors can remodel immunosuppressive tumour microenvironments, and suggest that FcγR engagement is an important consideration in anti-TIGIT antibody development.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:627 |
|---|---|
| Enthalten in: |
Nature - 627(2024), 8004 vom: 29. März, Seite 646-655 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Guan, Xiangnan [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 22.03.2024 Date Revised 03.04.2024 published: Print-Electronic ClinicalTrials.gov: NCT03563716 ErratumIn: Nature. 2024 Mar 13;:. - PMID 38480897 Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41586-024-07121-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369087984 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369087984 | ||
| 003 | DE-627 | ||
| 005 | 20240404234907.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240229s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41586-024-07121-9 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1364.xml |
| 035 | |a (DE-627)NLM369087984 | ||
| 035 | |a (NLM)38418879 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Guan, Xiangnan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.03.2024 | ||
| 500 | |a Date Revised 03.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT03563716 | ||
| 500 | |a ErratumIn: Nature. 2024 Mar 13;:. - PMID 38480897 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s), under exclusive licence to Springer Nature Limited. | ||
| 520 | |a Tiragolumab, an anti-TIGIT antibody with an active IgG1κ Fc, demonstrated improved outcomes in the phase 2 CITYSCAPE trial (ClinicalTrials.gov: NCT03563716 ) when combined with atezolizumab (anti-PD-L1) versus atezolizumab alone1. However, there remains little consensus on the mechanism(s) of response with this combination2. Here we find that a high baseline of intratumoural macrophages and regulatory T cells is associated with better outcomes in patients treated with atezolizumab plus tiragolumab but not with atezolizumab alone. Serum sample analysis revealed that macrophage activation is associated with a clinical benefit in patients who received the combination treatment. In mouse tumour models, tiragolumab surrogate antibodies inflamed tumour-associated macrophages, monocytes and dendritic cells through Fcγ receptors (FcγR), in turn driving anti-tumour CD8+ T cells from an exhausted effector-like state to a more memory-like state. These results reveal a mechanism of action through which TIGIT checkpoint inhibitors can remodel immunosuppressive tumour microenvironments, and suggest that FcγR engagement is an important consideration in anti-TIGIT antibody development | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a atezolizumab |2 NLM | |
| 650 | 7 | |a 52CMI0WC3Y |2 NLM | |
| 650 | 7 | |a B7-H1 Antigen |2 NLM | |
| 650 | 7 | |a Immune Checkpoint Inhibitors |2 NLM | |
| 650 | 7 | |a Receptors, IgG |2 NLM | |
| 650 | 7 | |a Receptors, Immunologic |2 NLM | |
| 650 | 7 | |a TIGIT protein, human |2 NLM | |
| 650 | 7 | |a T cell Ig and ITIM domain protein, mouse |2 NLM | |
| 700 | 1 | |a Hu, Ruozhen |e verfasserin |4 aut | |
| 700 | 1 | |a Choi, Yoonha |e verfasserin |4 aut | |
| 700 | 1 | |a Srivats, Shyam |e verfasserin |4 aut | |
| 700 | 1 | |a Nabet, Barzin Y |e verfasserin |4 aut | |
| 700 | 1 | |a Silva, John |e verfasserin |4 aut | |
| 700 | 1 | |a McGinnis, Lisa |e verfasserin |4 aut | |
| 700 | 1 | |a Hendricks, Robert |e verfasserin |4 aut | |
| 700 | 1 | |a Nutsch, Katherine |e verfasserin |4 aut | |
| 700 | 1 | |a Banta, Karl L |e verfasserin |4 aut | |
| 700 | 1 | |a Duong, Ellen |e verfasserin |4 aut | |
| 700 | 1 | |a Dunkle, Alexis |e verfasserin |4 aut | |
| 700 | 1 | |a Chang, Patrick S |e verfasserin |4 aut | |
| 700 | 1 | |a Han, Chia-Jung |e verfasserin |4 aut | |
| 700 | 1 | |a Mittman, Stephanie |e verfasserin |4 aut | |
| 700 | 1 | |a Molden, Nandini |e verfasserin |4 aut | |
| 700 | 1 | |a Daggumati, Pallavi |e verfasserin |4 aut | |
| 700 | 1 | |a Connolly, Wendy |e verfasserin |4 aut | |
| 700 | 1 | |a Johnson, Melissa |e verfasserin |4 aut | |
| 700 | 1 | |a Abreu, Delvys Rodriguez |e verfasserin |4 aut | |
| 700 | 1 | |a Cho, Byoung Chul |e verfasserin |4 aut | |
| 700 | 1 | |a Italiano, Antoine |e verfasserin |4 aut | |
| 700 | 1 | |a Gil-Bazo, Ignacio |e verfasserin |4 aut | |
| 700 | 1 | |a Felip, Enriqueta |e verfasserin |4 aut | |
| 700 | 1 | |a Mellman, Ira |e verfasserin |4 aut | |
| 700 | 1 | |a Mariathasan, Sanjeev |e verfasserin |4 aut | |
| 700 | 1 | |a Shames, David S |e verfasserin |4 aut | |
| 700 | 1 | |a Meng, Raymond |e verfasserin |4 aut | |
| 700 | 1 | |a Chiang, Eugene Y |e verfasserin |4 aut | |
| 700 | 1 | |a Johnston, Robert J |e verfasserin |4 aut | |
| 700 | 1 | |a Patil, Namrata S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nature |d 1945 |g 627(2024), 8004 vom: 29. März, Seite 646-655 |w (DE-627)NLM000008257 |x 1476-4687 |7 nnns |
| 773 | 1 | 8 | |g volume:627 |g year:2024 |g number:8004 |g day:29 |g month:03 |g pages:646-655 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41586-024-07121-9 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 627 |j 2024 |e 8004 |b 29 |c 03 |h 646-655 | ||